Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12605439-B2
Publication Date
2026-04-21
Expiration Date
Abstract
The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
Core Innovation
The invention relates to universal influenza vaccine compositions comprising influenza peptides that include CD8+ T cell epitopes and B cell epitope peptides, wherein the peptides are attached to nanoparticles. The B cell epitope peptide includes M2e, and the CD8+ T cell epitopes are provided as peptide sets associated with influenza virus-derived targets. The nanoparticle embodiment is described as gold glyconanoparticles, where carbohydrate moiety ligands are associated with the particle-peptide presentation.
The compositions are described to include, in addition to CD8+ epitopes, optionally CD4+ T cell epitope peptides, including extended or nested CD4 epitopes. The peptide sets are described with reference to specific SEQ ID NO ranges for CD8+ epitopes and for CD4+ epitopes, and the invention discusses that the immunogenic peptides interact with HLA supertypes to support coverage. The nanoparticle format is described as providing uptake/delivery advantages and includes built-in “danger signals,” which reduces reliance on traditional adjuvants.
The document further provides immunological support for the approach, including identification of conserved MHC class I-presented CD8+ T cell epitopes from infected cells and assessments of CTL cross-reactivity. It also describes in vivo CTL activation in HLA-A2 transgenic mice using peptide-gold nanoparticle formulations without added adjuvant, along with measures of activation such as IFN-γ and a CD107a activation marker. Additionally, it reports M2e-specific IgG responses and functional cross-reactivity/neutralization assays for the antibody component.
Claims Coverage
The claims coverage is not explicitly described in patent.
Not explicitly described in patent.
Stated Advantages
Induces both humoral and cellular immunity by combining B cell epitope peptides, including M2e, and CD8+ T cell epitopes in a universal influenza vaccine composition.
Supports broad cellular immune coverage through HLA supertype breadth concepts and peptide sets designed to interact with different HLA supertypes.
Provides nanoparticle advantages including improved uptake/delivery and built-in “danger signals,” reducing the need for traditional adjuvants.
Enables in vivo CTL activation in HLA-A2 transgenic mice without added adjuvant using peptide-gold nanoparticle formulations.
Promotes M2e-specific IgG responses with functional cross-reactivity/neutralization activity.
Documented Applications
Universal influenza vaccination using nanoparticle-attached influenza peptides comprising CD8+ T cell epitopes and B cell epitope peptides, including M2e, with optional CD4+ T cell epitope peptides.
Use of peptide-gold nanoparticle vaccine formulations for inducing CTL responses and measuring T cell activation markers and IFN-γ in HLA-A2 transgenic mice.
Elicitation of M2e-specific IgG responses and assessment of functional cross-reactivity/neutralization in the context described in the document.
Delivery routes referenced for the vaccine compositions include transdermal, intradermal, subcutaneous, and oral-buccal routes.
Interested in licensing this patent?